---
title: "ATXS.US (ATXS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATXS.US/news.md"
symbol: "ATXS.US"
name: "ATXS.US"
parent: "https://longbridge.com/en/quote/ATXS.US.md"
datetime: "2026-05-21T10:15:29.043Z"
locales:
  - [en](https://longbridge.com/en/quote/ATXS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATXS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATXS.US/news.md)
---

# ATXS.US (ATXS.US) — Related News

### [20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes](https://longbridge.com/en/news/284128708.md)
*2026-04-27T00:12:19.000Z*
> Ascletis Pharma Inc. has completed enrollment in its 13-week U.S. Phase II study of ASC30, an oral GLP-1R agonist for ty

### [Egetis Appoints Tiago Nunes as Chief Medical Officer](https://longbridge.com/en/news/282138262.md)
*2026-04-09T05:30:32.000Z*
> Egetis Therapeutics has appointed Tiago Nunes, MD, PhD, as Chief Medical Officer, effective May 1, 2026. Nunes, previous

### [Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report](https://longbridge.com/en/news/280335741.md)
*2026-03-24T14:35:11.000Z*
> Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

### [Ascletis Pharma: Its small molecule GLP-1R agonist ASC30 ultra-long-acting subcutaneous depot formulation targeting obesity indications has achieved positive topline results in a 24-week Phase II study in the United States](https://longbridge.com/en/news/278532121.md)
*2026-03-10T09:59:00.000Z*
> ASCLETIS-B announced that its small molecule GLP-1R agonist ASC30 has achieved positive results in a 24-week Phase II st

### [Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock News](https://longbridge.com/en/news/276770940.md)
*2026-02-24T09:30:00.000Z*
> Cosmos Health Inc. has appointed Dr. Dimitrios Iliopoulos, an expert in AI-driven drug discovery and clinical-stage biot

### [Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.](https://longbridge.com/en/news/276346867.md)
*2026-02-19T14:28:08.000Z*
> A recent study has provided valuable insights to assist business leaders in enhancing incentive design, inspiring field 

### [Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?](https://longbridge.com/en/news/274821102.md)
*2026-02-04T13:27:23.000Z*
> BioCryst Pharmaceuticals Inc. (BCRX) shares have fallen over 40% from their 52-week high of $11.31, currently trading ar